Tagged with B

Colombia Dr. Sanjay Machado, the Vice President of Global Operations and Integrations for JSS Medical Research Inc., (JSS) a Canadian based international Contract Research Organisation, elaborates on the rapid expansion of the company through strategic acquisitions, the full range of clinical research-related services of JSS and the company’s vision to expand…

Austria Dr. Kurt Zatloukal, national node director of the Bio-Banking and Bio-Molecular Resources Research Infrastructure of Austria (BBMRI Austria), discusses the challenges of collaboration between the private and academic pharmaceutical sectors and the importance of their work in advancing pharmaceutical innovation. Furthermore, he looks into the growing trend of personalised medicines…

Colombia Guillermo Browne, General Manager at MSD Colombia, reveals the strategic importance of the Colombian affiliate, hosting a global data management centre and regional pharmacovigilance operations, while highlighting the company’s commitment to continue advancing the therapeutic value of care and the clinical research landscape in Colombia. With 70 years of presence…

Brazil In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of the main regulatory updates implemented by ANVISA over the past two years, while providing insights into the collaboration opportunities he…

Austria Dr. Daniel Wallerstorfer, CEO and founder of Novogenia, a vibrant Austrian genetics company, discusses founding his own company and the innovative services Novogenia provides to ensure genetics are a staple part of global preventative measures. He also provides an insight into the future of genetic analysis and the positive overall…

Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.  Could you introduce our readers to the…

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Bulgaria Deyan Denev, Executive Director of the Association of the Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares a clear overview of the role of innovative pharmaceutical players within Bulgaria, and the association’s commitment to working with government to enlarge patients’ access to innovative medicines. How has the overall situation for innovative…

Colombia Felipe Jaramillo, president at ProColombia, the government agency in charge of strengthening the country’s image, describes how Colombia successfully transitioned from being a war-damaged country to a business destination attracting exports, foreign investments and tourists. As an introduction, can you please describe the main milestones that the organization has experienced…

Austria Daniela Homan, executive director of AmCham Austria, the representative and advocating voice of US companies in Austria, provides an in-depth analysis of the strategies being employed by the chamber and highlights the current concerns of US subsidiary CEOs in Austria. She also provides an overview of how the market has…

Colombia Antonio Cordova, general manager of seca Latin America, shares the story of the recent establishment of the affiliate in Colombia that serves as a regional center for operations within Latin America. You were appointed general manager for Latin America a year and half ago; what was your assigned mission when…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…